Biologically Refined Oncological Resectability for Hepatocellular Carcinoma
Journal of Hepato-Biliary-Pancreatic Sciences · 2026
DOI: 10.1002/jhbp.70119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2026. Verfasst von Kenta Aso und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatectomy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background/Purpose Oncological resectability criteria for hepatocellular carcinoma (HCC) have been proposed to guide multidisciplinary treatment, but their validation remains limited. Incorporating biological factors may improve prognostic stratification and identification of borderline‐resectable HCC.
Methods
Patients undergoing initial hepatectomy for HCC (2009–2022) were classified as resectable (R), borderline‐resectable (BR)1, or BR2. Stratification of overall survival (OS) and recurrence‐free survival (RFS) was compared with the BCLC staging system. R‐group patients with alpha‐fetoprotein (AFP) ≥ 400 ng/mL and des‐gamma‐carboxy prothrombin (DCP) ≥ 400 mAU/mL were subclassified as biological‐BR.
Results
Among 391 patients (R: 330; BR1: 23; BR2: 38), survival stratification was comparable to the BCLC classification. Twenty‐six R‐group patients were reclassified as biological‐BR, with higher microvascular invasion rates (42.3%) and 5 year OS and 3 year RFS similar to BR1 patients (54.9% vs. 51.3%, p = 0.457; 38.1% vs. 25.0%, p = 0.954). Combining Biological BR with BR1 significantly improved time‐dependent prediction of 6 month recurrence, with an area under the receiver operating characteristic curve (Refined: 0.803; Original: 0.658, p ≤ 0.001, BCLC: 0.608, p ≤ 0.001) and net reclassification improvement (0.220 vs. Original; 0.446 vs. BCLC).
Conclusions
Refinement using AFP and DCP identified a biologically aggressive subset within the R group and may improve early recurrence prediction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan.
ORCID-Profile: Kenta Aso, Yoshinori Takeda
Zitieren
APA
Aso, K., Takeda, Y., Takahashi, A., Irie, S., Hirata, Y., Ichida, H., Yoshioka, R., Kotera, Y., Mise, Y., & Saiura, A. (2026). Biologically Refined Oncological Resectability for Hepatocellular Carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.70119
Vancouver
Aso K, Takeda Y, Takahashi A, Irie S, Hirata Y, Ichida H, et al. Biologically Refined Oncological Resectability for Hepatocellular Carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences. 2026. doi:10.1002/jhbp.70119
BibTeX
@article{Aso2026,
author = {Aso, Kenta and Takeda, Yoshinori and Takahashi, Atsushi and Irie, Shoichi and Hirata, Yoshihiro and Ichida, Hirofumi and Yoshioka, Ryuji and Kotera, Yoshihito and Mise, Yoshihiro and Saiura, Akio},
title = {Biologically Refined Oncological Resectability for Hepatocellular Carcinoma},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2026},
doi = {10.1002/jhbp.70119}
}
EUVIMED